22:30 , Feb 2, 2018 |  BioCentury  |  Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
21:19 , Nov 18, 2016 |  BC Week In Review  |  Company News

uniQure restructuring news

uniQure said it will reduce headcount by 50-60 (20-25%) to about 190 by YE17 to focus on key pipeline projects. The company expects the job cuts will save €5-€6 million ($5.4-$6.4 million) annually, while reprioritizing...
23:50 , Nov 15, 2016 |  BC Extra  |  Company News

uniQure paring down gene therapy portfolio

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects. The company expects the job cuts will save EUR 5-6...
07:00 , Mar 9, 2015 |  BioCentury  |  Emerging Company Profile

AAVs for the CNS

Voyager Therapeutics Inc. has a pipeline of adeno-associated viral vector-based gene therapies and is developing novel vectors that are optimized for better distribution in the CNS, among other qualities. Third Rock Ventures launched Voyager about...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

AAV2-GDNF: Phase I started

uniQure said researchers at the University of California, San Francisco and the NIH's National Institute of Neurological Disorders and Stroke (NINDS) began an open-label, dose-escalation Phase I trial to evaluate AAV2-GDNF in about 24...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

AAV2-GDNF: Phase I start

Next month, researchers at the University of California (San Francisco, Calif.) and the NIH's National Institute of Neurological Disorders and Stroke (NINDS) will begin an open-label Phase I trial to evaluate AAV2-GDNF in about...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Amsterdam Molecular, uniQure deal

Amsterdam Molecular's board unanimously recommended dissolving the company's assets into newco uniQure in a stock deal. Amsterdam said it is facing a "precarious" financial position with cash expected to last until April and the deal...
01:40 , Feb 18, 2012 |  BC Extra  |  Company News

Amsterdam Molecular to transfer assets, delist

Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) said its board unanimously recommended dissolving the company's assets into newly formed uniQure B.V. (Amsterdam, the Netherlands) in a stock deal. Amsterdam said it is facing a "precarious" financial...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Company News

Amsterdam Molecular neurology, hematology, endocrine/metabolic news

Amsterdam Molecular discontinued development of Glybera after CHMP's second recommendation against approval of the product in the EU for lipoprotein lipase (LPL) deficiency. The company will also reduce headcount by 50% to 45...